



September 15, 2008

MannKind to Present at the UBS Global Life Sciences Conference

VALENCIA, Calif., Sept. 15 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the UBS Global Life Sciences Conference on Tuesday, September 23, 2008 at 10:00 AM (ET) at the Grand Hyatt in New York.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at <http://www.mannkindcorp.com>. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes Technosphere[®] Insulin, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit <http://www.mannkindcorp.com>.

SOURCE MannKind Corporation

CONTACT: Matthew J. Pfeffer, Corporate Vice President and Chief Financial Officer of MannKind Corporation, +1-661-295-4784, mpfeffer@mannkindcorp.com

Web site: <http://www.mannkindcorp.com>